SCHEMBL6656451

SCHEMBL6656451

CCC1SC(=O)N(Cc2cccc(NC(=O)c3cccs3)c2)N=C1c1ccc(OC)c(OC2CCCC2)c1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 10/20 0.49
PDE4B Q07343 9/20 0.49
PDE4C Q08493 8/20 0.49
PDE4D Q08499 8/20 0.49
ACKR3 P25106 5/20 0.43
QRFPR Q96P65 1/20 0.43
MET P08581 1/20 0.43
PDE3B Q13370 1/20 0.43
PDE3A Q14432 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
PDE5A O76074 1/20 0.42
PDE1A P54750 1/20 0.42
PDE1B Q01064 1/20 0.42
PDE1C Q14123 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6655992 0.93 PDE4A (0.50) PDE4APDE4BPDE4CPDE4DQRFPR
SCHEMBL6688494 0.93 KMT2A (0.49) PDE4APDE4BPDE4CPDE4DACKR3
SCHEMBL6684213 0.90 PDE4A (0.49) PDE4APDE4BPDE4CPDE4DMET
SCHEMBL6841799 0.89 PDE4A (0.49) PDE4APDE4BPDE4CPDE4DACKR3
SCHEMBL6660923 0.89 PDE4A (0.50) PDE4APDE4BPDE4CPDE4DACKR3
SCHEMBL6655599 0.88 PDE4D (0.49) PDE4APDE4BPDE4CPDE4DMET
SCHEMBL6657398 0.88 PDE4A (0.48) PDE4APDE4BPDE4CPDE4DACKR3
SCHEMBL6662513 0.88 PDE4D (0.52) PDE4APDE4BPDE4CPDE4DACKR3
SCHEMBL6654888 0.87 PDE4D (0.50) PDE4APDE4BPDE4CPDE4DMET
SCHEMBL144540 0.87 PDE4A (0.48) PDE4APDE4BPDE4CPDE4DACKR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235845-A1 Use of phosphodiesterase iv inhibitors MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2004-11-25 US disclosed
EP-1435958-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GmbH (DE) 2004-07-14 EP disclosed
WO-2003032993-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GMBH (DE) 2003-04-24 WO disclosed
EP-0763534-B1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GMBH (DE) 2003-02-26 EP disclosed
US-5859008-A Arylalkyl diazinones MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1999-01-12 US disclosed
EP-0763534-A1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GmbH (DE) 1997-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235845-A1 Use of phosphodiesterase iv inhibitors PDE4A, PDE3A, PDE3B PDE4A 1/4885PDE4B 4/4885PDE4C 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.